STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #187 by analyst upside · 2026-06-27
PRQR
ProQR Therapeutics N.V.
Healthcare · Market Cap $161M · P/E 0x
ANALYST PRICE TARGET
+480.1%
implied upside to consensus target
Current Price $1.53
Consensus Target $8.88
Bull Target $14.0
Bear Target $4.0
Analysts Covering 8
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
7
Hold
0
Sell
0
52-Week Low $1.33
52-Week High $3.1
YTD Return -23.1%
FUNDAMENTALS
Market Cap $161M
P/E Ratio (TTM) N/A
Forward P/E -2.3x
EPS (TTM) $-0.49
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $14M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.33
52-Week High $3.1
Current Price $1.53
Bear Target $4.0
Bull Target $14.0
● Now $1.53 ● Target $8.88
TRADING DATA
Avg Volume 842K
YTD Return -23.1%
Analyst Count 8
Consensus Buy
Upside to Target +480.1%
Last Updated 2026-06-27

ANALYST SUMMARY

ProQR Therapeutics N.V. (PRQR) is currently trading at $1.53 with a Wall Street consensus price target of $8.88, implying potential upside of 480.1% over the next 12 months. 8 analysts currently cover PRQR, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $14.0, while the most cautious has a target of $4.0.

PRQR operates in the Healthcare sector with a market capitalisation of $161M. The stock is down 23.1% year-to-date and is currently trading near the lower end of its 52-week range of $1.33 – $3.1.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PRQR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Chardan Capital — Reiterated
Buy → Buy 2026-04-09 33% win rate (6 calls)
Chardan Capital — Reiterated
Buy → Buy 2025-11-04 33% win rate (6 calls)
Chardan Capital — Reiterated
Buy → Buy 2025-08-08 33% win rate (6 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2025-06-27 40% win rate (10 calls)
JMP Securities reit
Market Outperform → Market Outperform 2025-06-27 Building track record
Oppenheimer — Reiterated
Outperform → Outperform 2025-05-13 14% win rate (7 calls)
Evercore ISI Group ● Initiated
Outperform 2025-04-29 Building track record
Chardan Capital — Reiterated
Buy → Buy 2025-03-14 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →